This week, researchers at the American Transplant Congress in Boston presented data worth paying attention to. An experimental drug called tegoprubart (te-goe-PROO-bart) outperformed tacrolimus in a clinical trial, showing superior kidney function from one month out, zero graft loss, and no biopsy-proven rejection episodes after the first six months. Side effects were significantly lower, too. When you spend your mornings popping pills and wondering what your kidney is doing while you sleep, a headline like this lands differently.
Drug to prevent organ rejection after kidney transplant tops standard treatment in trial ~ reuters.com
Related Posts:
Anti-Rejection Medications 101
A kidney biopsy for research
Matching Clinical Kidney Trials – Jeff